Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report
Journal
Medicine
Journal Volume
99
Journal Issue
43
Date Issued
2020-10-23
Author(s)
Abstract
Currently, the 5-year survival rate remains poor for patients with metastatic colorectal cancer (mCRC), and the purpose of therapy is to prolong survival while maintaining the quality of life. Trifluridine/tipiracil, an oral drug combining trifluorothymidine and a thymidine phosphorylase inhibitor, is indicated as salvage therapy for mCRC patients who have progressed after all available regimens. Combination of local treatments with systemic therapy such as trifluridine/tipiracil represents an apt management strategy for mCRC patients.
SDGs
Other Subjects
pyrrolidine derivative; thymine; tipiracil; trifluridine; adenocarcinoma; aged; cancer staging; case report; drug combination; human; liver tumor; male; pathology; peritoneum tumor; quality of life; rectum tumor; salvage therapy; Adenocarcinoma; Aged; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Staging; Peritoneal Neoplasms; Pyrrolidines; Quality of Life; Rectal Neoplasms; Salvage Therapy; Thymine; Trifluridine
Type
journal article